Immune responses in the liver are tightly regulated to preserve the integrity of this vital organ. Hepatotropic viruses such as HBV exploit the tolerogenic environment in the liver to establish persistent infection in around 350 million people worldwide. HBV is a noncytopathic virus; the liver disease it triggers, resulting in cirrhosis and hepatocellular carcinoma, is immune mediated 1 . HBV can elicit starkly contrasting outcomes, recognized as distinct clinical phases-replicating at extremely high levels for decades without clinically apparent liver disease ('immunotolerant' phase) or, in contrast, driving a marked necroinflammatory reaction (active liver disease). The immune mechanisms distinguishing these phases, and the transition between them, have not been established.
Immune responses in the liver are tightly regulated to preserve the integrity of this vital organ. Hepatotropic viruses such as HBV exploit the tolerogenic environment in the liver to establish persistent infection in around 350 million people worldwide. HBV is a noncytopathic virus; the liver disease it triggers, resulting in cirrhosis and hepatocellular carcinoma, is immune mediated 1 . HBV can elicit starkly contrasting outcomes, recognized as distinct clinical phases-replicating at extremely high levels for decades without clinically apparent liver disease ('immunotolerant' phase) or, in contrast, driving a marked necroinflammatory reaction (active liver disease). The immune mechanisms distinguishing these phases, and the transition between them, have not been established.
In chronic HBV infection (CHB), an inadequate HBV-specific T cell response can trigger a large non-antigen-specific cellular infiltrate, amplifying liver damage through bystander T cells [1] [2] [3] [4] [5] . Here we have explored how such responses are blunted in phases when there is ongoing viral replication without overt liver inflammation, representing a paradigm for the immunoregulation of tissue damage. We previously noted a proliferative defect in global T cell responses in CHB accompanied by CD3-ζ-chain downregulation, a hallmark of l-arginine deprivation 6 . We therefore postulated that nutrient deprivation might be a factor limiting T cell responses in the metabolically restricted environment of the liver. Recent data highlight the central role of the metabolic milieu in regulating immunity, with an increased requirement for amino acids imposed by the demands of mounting an effective immune response 7, 8 .
A cell type increasingly recognized to exert potent immunoregulation through metabolic manipulation is the MDSC. These immature myeloid cells expand in tumor infiltrates, downregulating local and systemic immune responses through, for example, the production of arginase I, which catabolizes l-arginine to deprive immune effectors of this amino acid 9 . Emerging data also implicate MDSCs in inhibiting antiviral immunity [10] [11] [12] [13] , but their potential for regulating amino acid metabolism has not been examined in individuals with HBV infection.
In this study we demonstrate expansion of the granulocytic subset of MDSCs in individuals sustaining HBV replication without necroinflammatory liver disease. Our data indicate that this protective effect may be mediated by the capacity of gMDSCs expressing arginase I to potently inhibit T cell responses. Our findings highlight the capacity of gMDSCs to moderate tissue damage in a common human infection by constraining nutrient supplies to proliferating T cells.
RESULTS gMDSC expansion in individuals with HBV replication without liver damage
Circulating frequencies of gMDSCs were quantified with the gating strategy indicated (Fig. 1a) , using freshly isolated samples as gMDSCs are cryosensitive 14 ( Supplementary Fig. 1a ). Flow cytometric identification of CD66b, CD16, and cytospin staining confirmed the granulocytic nature of the gMDSC population analyzed 15, 16 ( Supplementary Fig. 1b,c) .
The frequency of gMDSCs was higher (mean, eightfold; maximum, 20-fold) in a cohort of 84 individuals with CHB (Supplementary Table 1 ) as compared to 44 healthy controls (measured as a percentage of myeloid cells (Fig. 1b) and as absolute numbers ( Supplementary  Fig. 1d) ). This finding was reproduced in a separately sampled cohort (54 subjects with CHB, 55 healthy controls), although gMDSC frequencies were proportionately lower in this cohort, a difference attributable to blood collection in EDTA versus heparin (Supplementary Fig. 1e) .
In some subjects with CHB, the expanded population of gMDSCs accounted for as much as 45% of circulating myeloid cells (Fig. 1b) , whereas the frequency of the monocytic subset of MDSCs (mMDSCs) was not higher than in healthy controls (Fig. 1c) . The percentage of gMDSCs in CHB was highly variable (Fig. 1b and Supplementary  Fig. 1e) , with the spread not attributable to age or cytomegalovirus (CMV) serostatus ( Supplementary Fig. 1f,g ). However, females with CHB (known to be less likely than males to develop HBV-related liver inflammation 17 ) had higher frequencies of gMDSCs than males (Fig. 1d) . Examining virological parameters, gMDSC numbers did not correlate with viral load, serum titer of HBV surface protein (HBsAg), or the presence of the secretory 'e' antigen (HBeAg) ( Supplementary  Fig. 1h-j) ; no interdependent relationship between these variables was detected using multiple linear regression or principal component analysis (data not shown).
HBV is a noncytopathic virus, with disease activity attributed to the degree of immunopathology rather than to viral replication.
We therefore analyzed gMDSC frequencies in a subset of the primary cohort that could be classified by repeated assessment of clinical parameters into four major phases of disease activity: 'immunotolerants' , 'HBeAg + active disease' , 'inactive disease' , and 'HBeAg − active disease' (diagnostic cut-offs defined in Fig. 1e legend) . Donors sustaining HBV replication in the absence of liver inflammation (assessed by repeated serum alanine transaminase (ALT) quantitation) had significantly higher gMDSC frequencies (Fig. 1e) and absolute numbers (data not shown) than those with active liver disease.
In 42 individuals, liver biopsy tissue was available for histological assessment of immune-mediated pathology; the percentage of gMDSCs correlated inversely with their hepatic necroinflammatory score (Fig. 1f ) . These findings were concisely displayed via hierarchical clustering by Euclidean distance (Fig. 1g) . Clustering in an unsupervised manner based on similarity of ALT, necroinflammatory score, and gMDSC frequencies showed that a high frequency of gMDSCs was concordant with low serum ALT and necroinflammatory score. Immunotolerant and inactive disease clustered together, with HBeAg + and HBeAg − active disease forming a separate cluster. Taken together, these data implicate gMDSCs as having a role in protecting against liver disease during CHB.
Temporal dynamics of gMDSC frequencies in acute and chronic HBV flares To further dissect the relationship between HBV disease activity and gMDSCs, we analyzed the frequency of gMDSCs during the dynamic changes that characterize acute HBV infection in three individuals who, unusually, had been sampled from the initial preclinical phase until disease resolution. We confirmed that although gMDSC numbers (g) Unsupervised hierarchical clustering using Euclidean distance; dendrogram displaying similarity between clusters. Clinically assigned disease phase shown adjacent to plot (not used for analysis). Increasing color intensity (blue→red) corresponds to increasing gMDSC frequency, serum ALT (IU/liter), or necroinflammatory score (n = 42 CHB subjects; maximum Knodell score in this cohort, 9/18). Error bars, mean ± s.e.m.; *P < 0.05, **P < 0.01; ***P < 0.001; b and c, unpaired t test; d and e, one-way ANOVA (Tukey's multiple comparisons test); f, Pearson product-moment correlation coefficient.
are reduced by cryopreservation, they remain in direct proportion to ex vivo gMDSC frequency (Supplementary Fig. 1a) , allowing valid interpretation of longitudinal trends within these cryopreserved samples. In the two donors sampled before or at peak viremia, a clear temporal correlation between increases in gMDSCs and HBV load was observed, with these parameters subsequently decreasing in parallel as well (seen in Fig. 2a as percentage of myeloid and in Supplementary Fig. 2a as percentage of live leukocytes).
Subjects showed the delay between peak viremia and subsequent hepatic flare (measured by ALT increases to >2,000 IU/liter) characteristic of acute HBV. Analogous to our cross-sectional findings in chronic infection, gMDSC frequencies correlated inversely with serum ALT and were highest when there was a high level of viral replication without liver damage, decreasing when the acute flare of hepatic injury peaked (Fig. 2b , percentage of myeloid; Supplementary  Fig. 2b , percentage of live leukocytes). Samples obtained during the intermittent, spontaneous hepatic flares characteristic of HBeAg − chronic disease likewise showed a close inverse temporal relationship between liver inflammation and gMDSC frequencies (Fig. 2c , percentage of myeloid; Supplementary Fig. 2c , percentage of live leukocytes).
These findings are in line with data from the mouse lymphocytic choriomeningitis virus (LCMV) model, which show transient expansion of MDSCs during acute infection, contrasting with their more sustained expansion during persistent infection 10 . Our results provide direct ex vivo evidence for the expansion of human gMDSCs in acute HBV infection and their inverse temporal correlation with hepatic flares, further suggesting that they may suppress liver inflammation.
Degranulating arginase + gMDSCs in CHB without immunopathology We next tested the postulate that gMDSCs could suppress inflammation during CHB through the production of the enzyme arginase I. gMDSCs, along with low-density neutrophils, were the only circulating cell subsets that showed strong staining for arginase I (Fig. 3a and Supplementary Fig. 3a) , with consistently greater intensity than mMDSCs (Supplementary Fig. 3b ). Subjects with CHB had a high proportion of gMDSCs expressing arginase I (mean ± s.e.m., 81.2 ± 3.2%, data not shown). The proportion of arginase + gMDSCs circulating in subjects with CHB was markedly higher than in controls ( Fig. 3b) , particularly during the immunotolerant and inactive phases of CHB (Fig. 3c) .
ImageStream analysis showed a granular pattern of arginase I distribution throughout gMDSCs (Supplementary Fig. 3c ). Surface expression of CD63 was higher on gMDSCs in subjects with CHB than in healthy controls ( Supplementary Fig. 3d ), indicative of an enhanced capacity of gMDSCs to degranulate and release arginase I (refs. 18,19) . Serum arginase I was also higher in subjects with CHB than in controls ( Fig. 3d) and correlated with gMDSC frequency (Fig. 3e) , which is in line with this cell population being a major source of circulating npg arginase I. The preferential expansion of arginase + gMDSCs in subjects in the immunotolerant phase of CHB was mirrored by the increased circulating arginase I concentrations in these individuals ( Fig. 3f) and reflected in the inverse correlation between serum arginase I and ALT concentrations ( Fig. 3g and Supplementary Fig. 3e ).
Ex vivo evidence of selective l-arginine depletion in CHB To corroborate the functionality of arginase + gMDSCs, we used highperformance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) to quantitate l-arginine, the amino acid substrate of arginase I. Consistent with their expanded population of arginase + gMDSCs, individuals with CHB, particularly those without liver inflammation, had lower serum concentrations of l-arginine than healthy controls ( Fig. 3h and Supplementary Fig. 3f ). Concentrations of l-tryptophan, which is also implicated in immune regulation 20 , showed a trend toward reduction during CHB ( Supplementary  Fig. 3g ), whereas l-phenylalanine concentration did not differ from controls (Supplementary Fig. 3h) .
To further probe the contribution of HBV infection to the gMDSCdependent depletion of l-arginine, we obtained serum samples from seven individuals before and during antiviral therapy. We observed that l-arginine levels were partially restored in five out of seven subjects once HBV replication was suppressed by antivirals (Fig. 3i) , with the degree of l-arginine concentration increase robustly correlating with the extent of disease suppression (Fig. 3j) .
Accumulation of arginase + gMDSC in the liver
We next investigated whether the expanded population of gMDSCs circulating in subjects with CHB could home to the liver to regulate inflammation at the site of HBV replication. Simultaneous quantitation of gMDSCs from paired blood and surplus liver biopsy tissue from 36 subjects with CHB showed that gMDSCs accumulated in the liver (at maximum, 56% of intrahepatic myeloid cells (Fig. 4a) and 9% of total live liver cellular extracts (Supplementary Fig. 4a) ). By contrast, mMDSCs were reduced in the intrahepatic compared to the circulating compartment during CHB (Supplementary Fig. 4b ). Samples from a cohort of individuals with chronic HCV infection revealed that another hepatotropic viral infection could also drive gMDSC expansion in the blood and enrichment in the liver compartment ( Supplementary Fig. 4c,d ).
In individuals with CHB, intrahepatic gMDSCs expressed more arginase I and surface CD63 than their circulating counterparts (Fig. 4b,c) , consistent with an enhanced potential to release arginase I and mediate immunosuppression by l-arginine depletion within the liver. Arginase I levels were markedly higher in gMDSCs than in other cellular fractions in liver extracts (Supplementary Fig. 4e ). (i,j) Seven CHB subjects pre-and on-antiviral therapy (tx) (for >1 year) measured for l-arginine concentration in sera (i) and correlation between decline in liver inflammation on therapy (ALT, IU/liter) and recovery of l-arginine levels (j). Error bars, mean ± s.e.m.; *P < 0.05, **P < 0.01; ***P < 0.001; b, d and h, unpaired t-test; i, paired t-test; e, g and j, Pearson product-moment correlation coefficient; c and f, one-way ANOVA (Tukey's multiple comparisons test).
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An additional potential source of arginase I is necrotic hepatocytes, but this arginase has low extracellular stability from rapid loss of divalent metal ions and requires an alkaline pH for full activity [21] [22] [23] ( Supplementary Fig. 4f ). In contrast, arginase + gMDSCs coexpress azurophilic granules (identified by their expression of myeloperoxidase (MPO); Supplementary Fig. 4g ) that release a factor crucial for activating arginase I at physiological pH (ref. 24) , thereby stabilizing gMDSC-derived arginase. We then stained circulating gMDSCs for chemokine receptors that are potentially relevant to their mobilization or liver homing according to recent studies 25 . CCR2, which is critical for the mobilization of MDSCs from the bone marrow in LCMV-infected mice 10 , was expressed at high levels on mMDSCs but barely detectable on gMDSCs from both subjects with CHB and healthy controls (Fig. 4d) . Loss of signaling through another chemokine receptor, CXCR4, promotes the egress of immature granulocytes from the bone marrow 26, 27 ; CXCR4 was expressed at reduced levels on gMDSCs in CHB (Fig. 4d) , suggesting that its downregulation may have accelerated the mobilization of these cells during CHB. Expression of CXCR3 was markedly higher on gMDSCs in the liver than on those in the circulation (Fig. 4e and Supplementary  Fig. 4h ), whereas CXCR1 was expressed at high levels by both circulating and intrahepatic gMDSCs in CHB (Fig. 4f and Supplementary Fig. 4i) , potentially allowing them to interact with hepatic stellate cells, which can produce the chemotactic cytokine IL-8 (ref. 28 ). Hepatic stellate cells are specialized, liver-resident stromal cells recently reported to be able to support the expansion of MDSCs [29] [30] [31] . We isolated and cultured primary hepatic stellate cells (pHSCs) from healthy resected liver tissue and found that they increased the expansion of gMDSCs within peripheral blood mononuclear cells (PBMCs) from controls or subjects with CHB (Fig. 4g) . Taken together, these data suggest that downregulation of CXCR4 may favor the egress of gMDSCs from the bone marrow into the circulation during CHB, whereas their accumulation in the liver could be directed by their expression of CXCR3 and CXCR1 and supported by pHSCs. Their potential to interact with pHSCs was underscored by visualizing gMDSCs within the liver sinusoids in sections from HBV-infected livers, where they were present in close proximity with infiltrating T cells (Fig. 4h,i) . (f) MFI of CD3-ζ on CD3ε + T cells in relation to circulating gMDSC frequencies at multiple time points throughout acute HBV infection (n = 3 CHB subjects, upper panels) and spontaneous hepatic flares of HBeAg − CHB (n = 2 CHB subjects, lower panels).
npg gMDSCs suppress HBV-specific and bystander T cell responses To investigate whether gMDSCs had the potential to suppress the T cells they encounter in the liver, we tested their impact on the expansion of HBV-specific T cells in co-culture. HBV-specific T cell IFN-γ responses were rescued by depletion of gMDSCs ( Fig. 5a and Supplementary Fig. 5a ). Conversely, HBV-specific CD4 + and CD8 + T cell responses were almost completely abrogated by the addition of gMDSCs (Fig. 5a,b) . We next sought functional evidence that l-arginine deprivation by gMDSCs could suppress bystander T cell responses, which have a crucial role in amplifying HBV-related immunopathology in both mouse models and human disease 1, 3 . To investigate this we analyzed subjects with CHB for pooled influenza-, Epstein-Barr virus (EBV)-and CMVspecific T cell responses. Again, removal of gMDSCs increased the expansion of peptide-specific IFN-γ + T cells, whereas their readdition suppressed responses to these viruses in all donors (Fig. 5c,d) , even at an effector to target ratio of 1:4 ( Supplementary Fig. 5b) .
Treatment of gMDSCs with the specific arginase I inhibitor N-hydroxy-nor-l-arginine (nor-NOHA) reduced their suppressive activity, partially restoring T cell IFN-γ responses (Fig. 5e) . Addition of nor-NOHA to PBMCs produced marginal increases in T cell IFN-γ responses, which is congruent with the lower frequency of arginase + gMDSCs in unsorted PBMCs (Fig. 5e) . gMDSCs could likewise suppress other CD8 + T cell functions potentially contributing to liver damage (TNF-α and granzyme B production) in an arginase-dependent manner (Supplementary Fig. 5c,d) . T cells cultured with gMDSCs showed downregulation of CD3-ζ expression and impaired proliferative capacity, hallmarks of l-arginine deprivation 6, 32 ( Supplementary Fig. 5e ). gMDSCs obtained by flow cytometry instead of beadsorting (purity shown in Supplementary Fig. 5f ) similarly suppressed T cell cytokines and downregulated CD3-ζ expression (Supplementary Fig. 5g) .
To investigate the effect of gMDSCs on T cells directly ex vivo, we examined the temporal changes in CD3-ζ expression (as a hallmark of l-arginine deprivation) in parallel with fluctuations in gMDSC frequencies over the course of acute and chronic flares of HBV disease. In all subjects experiencing hepatic flares in whom gMDSCs had been quantitated longitudinally (Fig. 2) , we observed a striking ex vivo inverse temporal relationship between number of gMDSCs and CD3-ζ expression on global T cells (Fig. 5f) . These findings suggested that gMDSCs could impede the T cell responses capable of driving liver pathology by starving T cells of l-arginine.
l-arginine deprivation induces system L amino acid transporters Uptake of certain essential amino acids by T cells is dependent on the system L amino acid transporters, which have recently been shown to have a critical role in the metabolic reprogramming required for a proliferative response to T cell receptor (TCR)-mediated signaling 7, 33 . We therefore stained for CD98 on T cells to identify the family of system L amino acid transporters (Slc7a5, Slc7a6, Slc7a7, Slc7a8) that form heterodimers with the CD98 heavy chain 7, 34 . Ex vivo expression of CD98 on T cells was low, but it was higher in some individuals with CHB than in healthy controls ( Fig. 6a and  Supplementary Fig. 6a) . 
It has previously been shown that levels of Slc7a5 on rat hepatocytes can increase in response to l-arginine starvation 35 . We hypothesized that T cells infiltrating the extensive liver vasculature could be subjected to prolonged periods of l-arginine deprivation, manifested as a compensatory increase in Slc7a5 (and monitored by CD98 expression). To investigate this, we used paired blood samples and liver biopsy tissue from 11 individuals with CHB for the comparison of circulating and intrahepatic T cells. The number of T cells expressing CD98 directly ex vivo and the level of this expression were higher in the intrahepatic than in the circulating compartment in all subjects examined ( Fig. 6b and Supplementary Fig. 6b) . We therefore investigated the expression of CD98 on HBV-specific CD8 + T cells, which would have encountered their antigen in the liver milieu, identified directly ex vivo by HLA-A2-HBV-peptide multimer staining. HBV-specific CD8 + T cells had higher expression of CD98 than global CD8 + T cells in all subjects examined ( Fig. 6c and Supplementary  Fig. 6c ). HBV-specific CD8 + T cells also had consistently higher CD98 expression than their CMV-specific CD8 + T cell counterparts in the same individuals ( Fig. 6d and Supplementary Fig. 6d ), which in turn had higher CD98 expression than the global population of CD8 + T cells in these subjects with CHB ( Supplementary Fig. 6e ).
To test whether the higher CD98 expression we observed in intrahepatic and virus-specific T cells during CHB could represent a compensatory response to l-arginine deprivation, we starved TCR-stimulated T cells of l-arginine in vitro. We noted a progressive upregulation of CD98 expression on T cells in response to decreasing concentrations of l-arginine in the medium (Fig. 6e) . Following l-arginine deprivation, T cells with the highest upregulation of CD98 expression showed increased expression of the transferrin receptor CD71 (Fig. 6f) , suggestive of an alteration in cellular metabolism 7 . The compensatory increases in CD98 expression driven by l-arginine starvation were accompanied by substantial increases in the capacity of TCR-stimulated T cells to take up radioactively labeled phenylalanine (Fig. 6g) . This was due to the specific capacity of l-arginine deprivation to increase the function of the system L transporters used by essential, large, neutral amino acids such as phenylalanine and leucine, as the effect was abrogated using a small molecule inhibitor of these transporters (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, BCH) (Fig. 6h) . Thus, l-arginine starvation imposed on T cells by arginase + gMDSCs has the potential to drive reprogramming of their metabolic response to TCR engagement. DISCUSSION CHB is a highly prevalent disease in which the differential regulation of immune-mediated tissue damage results in markedly contrasting outcomes of infection. Using blood and liver samples from well-characterized cohorts with diverse clinical phases of acute and chronic disease, we demonstrate MDSC-mediated arginasedependent regulation of immunopathology. A subset of MDSCs with some characteristics of immature granulocytes (gMDSCs) is expanded in the circulation and liver during HBV infection, particularly in those individuals in whom HBV replicates at a high level without triggering overt immunopathology. gMDSCs potently suppress the proliferative expansion of HBV-specific and bystander T cell responses, which have been previously implicated in the liver damage triggered by HBV infection. The correlations between circulating gMDSC frequencies, arginase I concentrations, T cell ζ-chain expression, and the degree of liver pathology point to the relevance of metabolic immunoregulation in vivo. This is further reinforced by our data showing differential expression of key amino acid transporters on virus-specific and organ-infiltrating T cells that can be driven by l-arginine starvation and modulates uptake of other essential nutrients.
Human MDSCs have been shown to release arginase I upon degranulation 16 , which is consistent with the correlation we observed between gMDSC frequencies and serum arginase I concentrations. Necrotic hepatocytes are another source of arginase I (refs. 36,37); we previously postulated that transient increases in serum arginase I concentrations in acute 38 and chronic 6 flares of HBV infection might derive from damaged hepatocytes. We now show that increases in serum arginase I concentrations that occur during the immunotolerant and inactive phases of CHB are likely to derive predominantly from the concurrent increase in arginase + gMDSCs, as there is minimal hepatocyte damage in these settings. The depletion of l-arginine and accompanying global T cell changes noted in the circulation of individuals with CHB 6,38,39 are unlikely to be sufficient to markedly impair peripheral immune responses, in line with the lack of obvious generalized immunosuppression. However, in the local liver milieu, gMDSCs accumulate, express and degranulate more arginase I, and can be visualized in close association with T cells in the narrow-lumen sinusoidal vasculature; this should maximize the effects of local nutrient depletion and any contact-dependent interactions. Activation of locally infiltrating MDSCs to express more arginase I, allowing enhanced suppression of neighboring bystander T cell responses, has similarly been reported in a mouse tumor model 40 .
Depriving T cells of adequate supplies of l-arginine in vitro inhibits their proliferation by arresting them in G 0 /G 1 (ref. 41) and is reflected by CD3-ζ downregulation and defects in the expansion of functional responses during CHB 6 . The capacity of gMDSCs to deprive T cells of l-arginine is underscored by our new observation of a close inverse temporal correlation between gMDSC frequencies and T cell CD3-ζ-chain expression ex vivo. We show that virus-specific T cells can also differentially regulate their expression of key amino acid transporters in vivo, providing an additional rheostat to modulate the intracellular availability of amino acids in persistent viral infections. This is supported by recent work demonstrating that the system L transporter Slc7a5 functions as a critical checkpoint to control the metabolic response of T cells to antigen 7 . We find that compensatory upregulation of system L transporters in response to extracellular deprivation of l-arginine can enhance T cell uptake of essential amino acids like phenylalanine and leucine that, like l-arginine, regulate effector function through the mTOR kinase 7, 42 . This exemplifies a novel paradigm, whereby metabolically stressed T cells can attempt to reprogram themselves by selectively increasing their nutrient supply.
Although our data implicate arginase I as a major effector mechanism of the gMDSC population expanded in CHB, it is probable that they can utilize supplementary suppressive mechanisms 9 . In addition to suppressing HBV-specific and bystander T cells that mediate cytolysis and produce pro-inflammatory cytokines, it remains to be determined whether MDSCs can exert other anti-inflammatory effects in the HBV-infected liver. Future work should address whether gMDSCs can induce T reg cells to amplify their immunosuppressive effects 9 , inhibit the capacity of Kupffer cells to limit immunopathology 43 , or downregulate hepatic NK cells or monocytes that may contribute to bystander liver damage in HBV 4, 5, 44 . In support of this concept, work in other models has revealed inhibition of macrophage proinflammatory cytokines by MDSC 45 or l-arginine deprivation 46 .
What factors drive and maintain the expansion of suppressive gMDSCs in viral hepatitis? Our data from studies of early acute HBV infection support a role for the virus in contributing to gMDSC induction. The increased frequency of gMDSCs in hepatotropic infections npg and their enrichment and enhanced function in the intrahepatic compartment led us to question the role of the liver milieu in sustaining these cells. Hepatic stellate cells can promote immunosuppression by augmenting expansion of MDSCs in vitro [29] [30] [31] , as we observed, and in vivo 29 . The pathways involved, and whether they induce MDSC proliferation and/or enhance their survival, remain to be elucidated. In addition to the chemokine receptors we described, a number of other candidate drivers, including TNF-α, IL-6, vascular endothelial growth factor, hypoxia-induced HIF-1-α (refs. 9, 40, 47) , and γδT cells 48 , merit investigation for their potential contribution to the differential accumulation of gMDSCs in the distinct phases of CHB.
Our results point to a role for gMDSCs in sustaining the state of immunotolerance to high levels of HBV replication characterizing the first decades of infection. In addition, the higher frequencies of gMDSCs in female patients are in line with their threefold decreased risk of liver inflammation during CHB compared to men 17 . Patients in the immunotolerant phase of CHB, who constitute a huge infectious reservoir, have generally not been considered for antiviral therapy because of their reduced response rate and the view that their disease is immunologically inactive. However, recent findings challenge this dogma, highlighting the fact that T cells may be less exhausted at this earlier phase of infection 49 . Our results suggest that the immunotolerant phase is characterized by active downregulation of inflammatory immune responses rather than immune ignorance, which raises the possibility of targeting MDSCs or amino acid metabolism to manipulate T cell responses. An important first step will be to investigate whether the expanded population of arginase + gMDSCs can be corrected if subjects in the immunotolerant phase are treated with existing antivirals. More broadly, our findings point to the need to investigate the role of MDSCs in other types of liver disease and underscore the importance of metabolic regulation of immunopathology in the setting of chronic antigenic stimulation.
METHODS
Methods and any associated references are available in the online version of the paper.
